Pembrolizumab + Carboplatin + Cisplatin + Pemetrexed + Lenvatinib + Placebo matching lenvatinib
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Nonsquamous Non-small Cell Lung Cancer
Conditions
Nonsquamous Non-small Cell Lung Cancer
Trial Timeline
Mar 25, 2019 → Aug 30, 2024
NCT ID
NCT03829319About Pembrolizumab + Carboplatin + Cisplatin + Pemetrexed + Lenvatinib + Placebo matching lenvatinib
Pembrolizumab + Carboplatin + Cisplatin + Pemetrexed + Lenvatinib + Placebo matching lenvatinib is a phase 3 stage product being developed by Eisai for Nonsquamous Non-small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03829319. Target conditions include Nonsquamous Non-small Cell Lung Cancer.
What happened to similar drugs?
0 of 3 similar drugs in Nonsquamous Non-small Cell Lung Cancer were approved
Approved (0) Terminated (0) Active (3)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04716933 | Phase 3 | Completed |
| NCT03829319 | Phase 3 | Completed |
Competing Products
7 competing products in Nonsquamous Non-small Cell Lung Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pemetrexed + Erlotinib + Pemetrexed + Erlotinib | Eli Lilly | Phase 2 | 35 |
| Patritumab Deruxtecan + Platinum-based chemotherapy | Daiichi Sankyo | Phase 3 | 44 |
| Pembrolizumab + Carboplatin + Cisplatin + Pemetrexed + Lenvatinib + Placebo matching lenvatinib | Eisai | Phase 3 | 40 |
| Pemetrexed | Eli Lilly | Phase 2 | 35 |
| Pembrolizumab + Pemetrexed + Carboplatin + Cisplatin + Olaparib | Merck | Phase 3 | 40 |
| Erlotinib | Roche | Pre-clinical | 26 |
| Pemetrexed + Carboplatin + demcizumab | Mereo BioPharma | Phase 2 | 25 |